Journal of Eye and Ophthalmology

Journal of Eye and Ophthalmology

ISSN 2055-2408
Original Research

Half-dose and half-fluence photodynamic therapy for central serous chorioretinopathy

Julie M. Rosenthal1† and Christina J. Flaxel2*

*Correspondence: Christina J. Flaxel

These authors contributed equally to this work.

2. Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.

Author Affiliations

1. Retinal and Ophthalmic Consultants, Northfield, New Jersey, USA.


Background: Chronic central serous chorioretinopathy presents a treatment challenge. Photodynamic therapy has been used successfully but with side effects; thus, the authors explored half-dose and half-fluence photodynamic therapy as lower-risk alternatives.

Methods: Retrospective medical record review of patients with chronic or recurrent central serous chorioretinopathy who received half-dose or half-fluence photodynamic therapy from May 2008 through March 2011 at a tertiary care referral center in Portland, Oregon, USA. The authors recorded demographics, visual acuity, and change in central retinal thickness as measured by optical coherence tomography.

Results: Eight patients aged 46 to 80 years (11 eyes) were treated for central serous chorioretinopathy with half-dose or half-fluence photodynamic therapy, or with both of these treatment modalities on different occasions. Visual acuity before treatment ranged from 20/15 to 20/100; after treatment, visual acuity also ranged from 20/15 to 20/100. The authors noted no significant differences between half-dose and half-fluence photodynamic therapy and no serious treatment complications.

Conclusions: Half-dose and half fluence photodynamic therapy are safe and effective treatment alternatives for chronic central serous chorioretinopathy.

Keywords: Central serous chorioretinopathy, photochemotherapy, retina, retinal detachment, retinal pigment epithelium

ISSN 2055-2408
Volume 1
Abstract Download